| Literature DB >> 35729944 |
A L Stalinskaya1, S Y Chikunov1, I A Pustolaikina2, I V Kulakov1.
Abstract
Computational study of some details of the cyclization reaction between 3,5-diacetyl-2,6-dimethylpyridine and salicylic aldehyde in an acidic medium was performed by the DFT RB3LYP/6-31G method using the Gaussian-2016 software package. It was shown that protonation of the pyridine nitrogen atom leads to a significant increase in the charge of the hydrogen atom of the 2-methyl group of pyridine and the methyl acetyl group. This leads to the growth of the methyl group CH-acidity and enolization of the acetyl group. It was also found that the protonated tautomeric enol form of 3,5-diacetyl-2,6-dimethylpyridine gives a stable pre-reaction complex with salicylic aldehyde due to the formation of three hydrogen bonds. The formation of this pre-reaction complex, apparently, leads to the implementation of the Knoevenagel reaction, instead of the alternative possible Claisen-Schmidt reaction of salicylic aldehyde at the acetyl group of pyridine. The possible biological activity of the previously obtained cyclization products was evaluated by molecular docking using the AutoDock Vina software. Some cyclization products showed higher values of the binding affinity with the selected target proteins in comparison with the known antiviral drugs Nevirapine and Favipiravir. The results obtained confirm the correctness of the proposed cyclization mechanism between 3,5-diacetyl-2,6-dimethylpyridine and salicylic aldehyde. This also makes it possible to assess the prospects of previously obtained derivatives of epoxybenzo[7,8]oxocino[4,3-b]pyridine as synthetic analogs of natural integrastatins A, B for further synthesis and study of their antiviral activity. © Pleiades Publishing, Ltd. 2022.Entities:
Keywords: 3,5-diacetyl-2,6-dimethylpyridine; integrastatins A and B; intramolecular cyclization; molecular docking; molecular modeling; reaction mechanism; tetracyclic epoxybenzooxocine
Year: 2022 PMID: 35729944 PMCID: PMC9197093 DOI: 10.1134/S107036322205022X
Source DB: PubMed Journal: Russ J Gen Chem ISSN: 1070-3632 Impact factor: 0.779
Scheme
Fig. 1. ORTEP representation of the molecular structure of compound 3a.
Some bond lengths in the molecule of compound 3a according to single crystal X-ray diffraction and DFT calculation data (RB3LYP 6-31G)
| Bond | Bond length, Å | Absolute error, Å | Relative error, % | |
|---|---|---|---|---|
| РСА | RB3LYP 6-31G | |||
| N1–C2 | 1.3411 | 1.35383 | 0.01273 | 0.94 |
| C3–C15 | 1.5042 | 1.49001 | 0.01419 | 0.94 |
| C5–O6 | 1.4472 | 1.48048 | 0.03328 | 2.29 |
| O6–C6A | 1.3798 | 1.40020 | 0.02040 | 1.47 |
| N1–C12A | 1.3447 | 1.35014 | 0.00544 | 0.40 |
| O1–C15 | 1.2101 | 1.24919 | 0.03909 | 3.23 |
| C5–O13 | 1.4075 | 1.43966 | 0.03216 | 2.28 |
| C11–O13 | 1.4406 | 1.47891 | 0.03831 | 2.65 |
| C2–C3 | 1.4058 | 1.42515 | 0.01935 | 1.37 |
| C15–C16 | 1.493 | 1.51951 | 0.02651 | 1.77 |
| C4A–C5 | 1.5272 | 1.52507 | 0.00213 | 0.13 |
| C4A–C12A | 1.3939 | 1.40509 | 0.01119 | 0.80 |
Scheme
Scheme
Scheme
Optimized geometry and calculated charge characteristics of salicylic aldehyde, compounds 1 and 3a
| Compound | Structural formula | Optimized geometry and Mulliken charges |
|---|---|---|
| 3,5-Diacetyl-2,6-dimethylpyridine |
|
|
| Salicylic aldehyde |
|
|
| Oxocin |
|
|
Optimized geometry and some calculated characteristics of structures of the stage 1
| Compound | Structural formula | Optimized geometry and Mulliken charges | |
|---|---|---|---|
| 3,5-Diacetyl-2,6-dimethylpyridine ( |
|
| –632.0234 |
| Protonated form of 3,5-diacetyl-2,6-dimethylpyridine ( |
|
| –632.4010 |
| Double protonated form of 3,5-diacetyl-2,6-dimethylpyridine ( |
|
| –632.6083 |
| Enol form of 3,5-diacetyl-2,6-dimethylpyridine ( |
|
| –632.3911 |
Scheme
Scheme
Scheme
Binding affinity (kcal/mol) for complexes of proteins 3V81 and 7AAP with native ligands and compounds 3a–3h
| Ligand | 3V81 | 7AAP |
|---|---|---|
| Nevirapine | –7.5 | – |
| Favipiravir-RTP | – | –6.3 |
|
| –7.9 | –6.2 |
|
| –8.1 | –7.4 |
|
| –8.2 | –7.6 |
|
| –8.6 | –7.5 |
|
| –8.6 | –7.4 |
|
| –8.7 | –8.0 |
|
| –8.8 | –8.2 |
|
| –9.1 | –8.0 |
Fig. 2. Сomplex between oxocino[4,3-b]pyridine 3h and HIV-1 reverse transcriptase (3V81). (a) 3D Docking model and (b) 2D docking model.
Fig. 3. Сomplex between oxocino[4,3-b]pyridine 3g and SARS-CoV2 RNA dependent RNA polymerase (7AAP). (a) 3D Docking model and (b) 2D docking model.